Rutgers & Horizon plan to commercialize CRISPR base editing technology
Category: #health  By Saipriya Iyer  Date: 2019-01-29
  • share
  • Twitter
  • Facebook
  • LinkedIn

Rutgers & Horizon plan to commercialize CRISPR base editing technology

Horizon has also agreed to fund further research in base editing at the Rutgers University.

Horizon Discovery Group plc, one of the globally reputed gene editing industry contenders, has reportedly inked a partnership with The State University of New Jersey, Rutgers. As per reliable sources, the agreement has been forged for developing and commercializing a gene editing technology – called base editing, that finds applications in new cell therapy development and is expected to augment Horizon’s research tools and services.

Credible reports cite that Horizon will join hands with the Rutgers University to develop the novel base editing platform from Dr. Shengkan Jin laboratory. As a part of the agreement, Horizon has already made a non-material payment to Rutgers, garnering the option to exclusively license the base editing technology to be used in all therapeutic applications. Sources familiar with the knowledge of the matter also claim that Horizon will fund further research in base editing at the Rutgers University while simultaneously undertaking evaluation and proof-of-concept studies at Horizon.

A report published by Genomeweb claims Terry Pizzie, CEO, Horizon, to have stated that base editing is one of the most potentially transformative of all gene editing technologies and is equipped with the ability to target numerous diseases that so far have no treatment. As a global leader in the field of gene modulation and gene editing, both in the applied as well as research markets, Horizon is rather thrilled to join forces with the Rutgers University, Pizzie added.

Further commenting on the partnership, Pizzie said that by extending Horizon’s scientific and IP capabilities, the company will now be more than able to completely support its pharma, academic, and biotech partners to deliver enhanced cell therapy solutions to patients. Also, as a part of its five-year investment strategy, Horizon is committed to pouring in capital in high-grade technologies which maintain its market leadership – base editing technology being the case in point, he elaborates.



About Author

Saipriya Iyer

Email: [email protected]   

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

Read More

More News By Saipriya Iyer

Raspberry Pi opens its inaugural brick-and-mortar retail store
Raspberry Pi opens its inaugural brick-and-mortar retail store
By Saipriya Iyer

Raspberry Pi is one among the many online retailers that is expanding offline to gain more customers.

Raspberry Pi has reportedly opened its very first brick-and-mo...

Orchard Therapeutics to present clinical data for OTL-101 & OTL-102
Orchard Therapeutics to present clinical data for OTL-101 & OTL-102
By Saipriya Iyer

Biopharma major Orchard Therapeutics has reportedly made it to the front page for having announced details of oral and poster presentations for new clinical data. As per sources familiar with the knowledge of the matte...

Otsuka-Click alliance on digital therapeutics to help MDD patients
Otsuka-Click alliance on digital therapeutics to help MDD patients
By Saipriya Iyer

Otsuka America, Inc., and Click Therapeutics, Inc., have reportedly announced that they have signed an agreement to develop and commercialize a digital therapeutic for the treatment of MDD. The partnership aims to prov...